Gastrointestinal stromal tumour Program in Pharmaceutical Benefits Scheme (PBS) 012-18053000
Expand allThis document outlines details of PBS-subsidised imatinib, ripretinib and sunitinib for patients with gastrointestinal stromal tumour (GIST).
For information on how to process a PBS Authority see Processing Complex Authority Required Listings. Contact a Local Peer Support (LPS) if unsure on how to action an application.
Gastrointestinal stromal tumour (GIST) quick reference
|
Restrictions |
Authority level and section |
PA assessment |
Processing system |
Prescriber type |
Prescriber self-serve |
|
Initial Adjuvant or Metastatic/Unresectable |
Telephone Electronic S85: |
No |
OPA |
Not specified |
Yes |
|
Initial Metastatic/Unresectable PB096 form |
Written Electronic S85: |
No |
OPA |
Not specified |
Yes |
|
Initial Metastatic/Unresectable |
Telephone Electronic S85: ripretinib |
No |
OPA |
Not specified |
Yes |
|
Continuing Adjuvant or Metastatic/Unresectable |
STREAMLINED S85: |
No |
OPA |
Not specified |
N/A |
|
Continuing Metastatic/Unresectable |
STREAMLINED S85: sunitinib |
No |
OPA |
Not specified |
N/A |
|
Continuing Metastatic/Unresectable |
Telephone Electronic S85: |
No |
OPA |
Not specified |
Yes |